Becton Dickinson and Co (NYSE:BDX) CEO Vincent A. Forlenza sold 16,866 shares of the stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $237.61, for a total value of $4,007,530.26. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

BDX opened at $240.04 on Friday. The firm has a market cap of $63.20 billion, a PE ratio of 21.80, a P/E/G ratio of 1.63 and a beta of 1.19. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. Becton Dickinson and Co has a fifty-two week low of $209.91 and a fifty-two week high of $265.87.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the consensus estimate of $2.93. The business had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The company’s revenue was up 39.0% compared to the same quarter last year. During the same period last year, the company posted $2.40 EPS. Equities research analysts forecast that Becton Dickinson and Co will post 12.15 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on the company. Morgan Stanley increased their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Wells Fargo & Co increased their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Citigroup increased their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Royal Bank of Canada reaffirmed a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, KeyCorp reaffirmed a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $253.79.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDX. Acropolis Investment Management LLC bought a new stake in shares of Becton Dickinson and during the 3rd quarter worth $101,000. Almanack Investment Partners LLC. acquired a new stake in shares of Becton Dickinson and in the second quarter worth $105,000. Truvestments Capital LLC acquired a new stake in shares of Becton Dickinson and in the third quarter worth $105,000. Bartlett & Co. LLC boosted its position in shares of Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 435 shares during the period. Finally, Bridgeworth LLC acquired a new stake in shares of Becton Dickinson and in the second quarter worth $131,000. 92.70% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Vincent A. Forlenza Sells 16,866 Shares of Becton Dickinson and Co (BDX) Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/11/16/vincent-a-forlenza-sells-16866-shares-of-becton-dickinson-and-co-bdx-stock.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Reverse Stock Split

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.